

each of the formulations based on Betamethasone, Hydrocortisone and its derivatives;

(b) when the production of each of the items based on Betamethasone and Hydrocortisone and its derivatives was started with detail of production during the last three years; and

(c) whether any of these items is covered or is proposed to be covered under COB Licence, if so, on what basis and what are the reasons for delaying the decisions in this behalf?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) to (c) Information is being compiled and will be laid on the Table of the House.

**Revocation of Industrial Licences of M/s. Glaxo Ltd. for manufacture of bulk drugs**

1719. SHRI B. C. PATTANAYAK: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact that Government monitors implementation of industrial licences for the manufacture of bulk drugs;

(b) if so, the reasons for which Government have not revoked the industrial licences of M/s. Glaxo Ltd. for the manufacture of 21 bulk drugs licensed to them which they have not manufactured during the past five years; and

(c) what are the rules and regulations for revoking industrial licences and how long it takes for Government to revoke a licence?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) Yes, Sir.

(b) A show cause notice for revoking 3 industrial licences

covering 10 bulk drugs has been issued to M/s. Glaxo. A final decision will be taken after obtaining all the requisite information from the company. A decision has also been taken to amend the letter of intent for expansion deleting 4 bulk drugs from their existing approvals for the manufacture of Corticosteroids. The remaining bulk drugs are part of partially implemented licences.

(c) Under Section 12 of the Industries (D&R) Act, 1951 Government is empowered to revoke an Industrial Licence where it is satisfied that the licensee has without reasonable cause failed to establish or to take effective steps to establish the manufacture of the items licensed, within the time specified or within such extended time granted by the Government Under Rule 17 of the Registration and the Licensing Undertakings Rules 1952, the licensee has to be given an opportunity to state his case before a decision is taken for revocation.

**Fixation of Price of Betamethasone on the basis of 16-DPA**

1720. DR. JOSEPH LEON D'SOUZA: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to state.

(a) whether it is a fact that the fair prices fixed by Government on May 12, 1981 for betamethasone/derivatives were based on M/s. Glaxo Ltd. producing their own 16-DPA to three-fourths of their total consumption of this item;

(b) if so, what has been the quantity of 16-DPA utilised by M/s. Glaxo Limited and their production of betamethasone/derivatives during the past three years and the break-up of this indicating production and procurement, resources of procurement and prices paid thereof; and

(c) what steps are proposed to be taken by Government and by when to further reduce the prices of betamethasone/derivatives on the basis of the lower prices of 16-DPA as compared to that taken in Glaxo's costing of betamethasone/derivatives?

THE MINISTER OF STATE IN THE MINISTRY OF PETROLEUM, CHEMICALS AND FERTILIZERS (SHRI DALBIR SINGH): (a) The prices of Betamethasone/derivatives notified by Government on 12th May, 1981 were based on the recommendations of the Bureau of Industrial Costs & Prices (BICP). While working out these prices on the basis of the data submitted by the company, the BICP assessed that out of a requirement of 2020 kgs., of 16-Dehydro Pregnaolone Acetate (16-DPA) for the production of the envisaged quantities of Betamethasone/derivatives, M/s. Glaxo Laboratories will be using 1500 kgs., of their own produced 16-DPA (nearly 75 per cent) and will procure the rest.

(b) The production of Betamethasone and its derivatives by M/s. Glaxo Laboratories (India) Limited during the past three years is as follows:—

Year	Production (Kg.)
1978-79	280.00
1979-80	348.17
1980-81	425.21

M/s. Glaxo Laboratories (India) Limited vide their letter dt. 18th January, 1982 have reported the following production and procurement of 16-DPA during the past three years:

Year	Production (Kg.)	Procurement (Kg.)
1978-79	600	Not reported
1979-80	564	750
1980-81	1106	1266.2

During 1979-80 16-DPA was procured at a price varying from Rs. 2268/- per kg. to Rs. 2592/- per kg. and during the year 1980-81 the price of procurement varied from Rs. 1998/- per kg. to Rs. 2700/- per kg. M/s. Glaxo Laboratories (I) Ltd. also reported that out of the above three years during 1980-81 only they imported 25 kgs. of 16-DPA which was found to be sub-standard and as such was not used. As regards utilisation of 16-DPA the Cost Audit Report of M/s. Glaxo Laboratories (I) Limited for the year ending 30th June, 1981 shows a utilisation of 2483.96 kg.

(c) BICP have already been requested to undertake fresh examination of the cost structure of M/s. Glaxo Laboratories (I) Limited for the production of Betamethasone and its derivatives keeping in view the imports/procurement of various raw materials and chemicals required for its production. Further steps to revise the price of Betamethasone and its derivatives, if need be, would be possible only after the recommendations of the BICP are received and analysed.

#### Production of Hydrocortisone and Semi Succinate

1721. SHRIMATI AZIZA IMAM: Will the Minister of PETROLEUM, CHEMICALS AND FERTILIZERS be pleased to refer to the answer to the Unstarred Question 2640 given in the Rajya Sabha on the 21st December, 1981 and state:

(a) whether production of Hydrocortisone and Semi Succinate by indigenous manufacturers is authorised under Industries and Regulation Act, 1951;

(b) if so, what are the names of raw materials specified in the Industrial licence application for this product; and